Wellington Management Group LLP Acquires 55,051 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Wellington Management Group LLP grew its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 8.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 699,814 shares of the company’s stock after purchasing an additional 55,051 shares during the quarter. Wellington Management Group LLP’s holdings in Intellia Therapeutics were worth $8,160,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. ARK Investment Management LLC raised its stake in Intellia Therapeutics by 2.3% in the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock worth $146,174,000 after buying an additional 280,946 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Intellia Therapeutics by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company’s stock worth $118,816,000 after purchasing an additional 562,249 shares during the last quarter. State Street Corp boosted its position in Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after purchasing an additional 780,754 shares in the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in Intellia Therapeutics in the fourth quarter valued at about $43,177,000. Finally, Geode Capital Management LLC raised its holdings in Intellia Therapeutics by 2.2% in the third quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock worth $48,164,000 after purchasing an additional 49,367 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

NTLA stock opened at $6.77 on Friday. Intellia Therapeutics, Inc. has a one year low of $5.90 and a one year high of $28.18. The firm’s fifty day moving average is $9.19 and its 200 day moving average is $12.68. The firm has a market cap of $700.81 million, a PE ratio of -1.24 and a beta of 2.23.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Morgan Stanley cut shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $56.00 to $11.00 in a report on Monday, January 27th. HC Wainwright assumed coverage on Intellia Therapeutics in a research report on Wednesday, March 5th. They set a “buy” rating and a $30.00 price target on the stock. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Barclays reduced their target price on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Finally, The Goldman Sachs Group restated a “sell” rating and set a $9.00 price target on shares of Intellia Therapeutics in a research note on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.